EXEL Exelixis
$58.33 -0.88%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-0.88%
YTD
+47.20%
P/E
16.9
P/B
5.44
ROE
42.5%
Div yield
—
Beta
0.56
Market cap
$14.5B
RSI (14)
55
Next earnings
Nov 2, 2026
Previous session
close of Oct 6, 2026 · EOD, no live order bookOpen
$58.85
Close
$58.33
VWAP (n/a)
—
Day high
$59.00
Day low
$57.02
Volume
2.0M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Exelixis Shares Rising on CABOMETYX Revenue
Yahoo Finance · Sep 30
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Yahoo Finance · Sep 24
Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?
Yahoo Finance · Sep 17
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle
Yahoo Finance · Sep 15
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises
Yahoo Finance · Sep 14
EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term
Yahoo Finance · Sep 11
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Sep 11, 2026 View → 8-K Aug 31, 2026 View → 10-Q Aug 5, 2026 View → 8-K Aug 5, 2026 View → 8-K May 29, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell EXEL. Try it in the Lab to size a position and see the risk.